rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

William Richard White

Director

Company insider

Files Form 4 as: Director, Disc Medicine; Director, Ventyx Biosciences; Chief Financial Officer, Akero Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
215
Buys
0
Sells
44
Bought
$0
Sold
$19.1M
Companies
3
Companies where not an officer
2
First trade
13 Dec 2019
Last trade
18 Jun 2026
Last filed
23 Jun 2026

Companies traded

Where they are an officer
Akero TherapeuticsOfficer · last 9 Dec 20250 buys · 32 sells
Everywhere else they filed: board seats, 10% stakes, other companies
IRON Disc MedicineDirector · Biotechnology · last 18 Jun 20260 buys · 11 sells
Ventyx BiosciencesDirector · Biotechnology · last 4 Mar 20260 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
18 Jun 2026filed 23 Jun 2026IRON Disc Medicineoption or derivative · BiotechnologySEC FORM 4 Code A—6,212 at $0.00filing
18 Jun 2026filed 23 Jun 2026IRON Disc Medicineoption or derivative · BiotechnologySEC FORM 4 Code A—6,212 at $0.00filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—33,000filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—40,000filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—20,000filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivativeSEC FORM 4 Code D—33,000filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivativeSEC FORM 4 Code D—40,000filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivativeSEC FORM 4 Code D—20,000filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivativeSEC FORM 4 Code D—119,120filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivativeSEC FORM 4 Code D—21,825filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivativeSEC FORM 4 Code D—15,937filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—119,120filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—21,825filing
4 Mar 2026filed 4 Mar 2026Ventyx Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—15,937filing
9 Dec 2025filed 9 Dec 2025Akero Therapeuticsoption or derivativeSEC FORM 4 Code D—3,421filing
9 Dec 2025filed 9 Dec 2025Akero Therapeuticsoption or derivativeSEC FORM 4 Code D—5,032filing
9 Dec 2025filed 9 Dec 2025Akero Therapeuticsoption or derivativeSEC FORM 4 Code D—2,328filing
9 Dec 2025filed 9 Dec 2025Akero Therapeuticsoption or derivativeSEC FORM 4 Code D—4,739filing
9 Dec 2025filed 9 Dec 2025Akero Therapeuticsoption or derivativeSEC FORM 4 Code D—3,527filing
9 Dec 2025filed 9 Dec 2025Akero Therapeuticsoption or derivativeSEC FORM 4 Code D—18,964filing

Sectors

Health Care11
Not placed33

Buys in green, sells in red, by the company’s sector.

Related people

Seth Loring HarrisonDirector · Director at Akero Therapeutics, filing Form 4 there in the last year
Mark T. IwickiDirector · Director at Akero Therapeutics, filing Form 4 there in the last year
Jane HendersonChief Financial Officer · Director at Akero Therapeutics, filing Form 4 there in the last year
G. Walmsley GrahamDirector · Director at Akero Therapeutics, filing Form 4 there in the last year
Andrew ChengDirector · President and CEO at Akero Therapeutics, filing Form 4 there in the last year
Kevin BittermanDirector · Also traded IRON in the last 90 days
Jonathan Yen-Wen YuChief Operating Officer · Also traded IRON in the last 90 days
John D. QuiselDirector · Also traded IRON in the last 90 days